Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases)
Jan Storek(University of Washington), David G. Maloney(Fred Hutch Cancer Center), John A. Hansen(University of Washington), Keith M. Sullivan(Duke Medical Center), Daniel E. Fürst(University of California, Los Angeles), Markus Reindl(Innsbruck Medical University), Eugene C. Lin(National Chung Cheng University), Richard A. Nash(Colorado Blood Cancer Institute), Yoshiki Akatsuka(Nagoya University), Rainer Storb(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Thomas Berger(University Medical Center Freiburg), Tomáš Kalina(Charles University), Monja D. Metcalf(University of Washington), Zhao Zhao(East China Normal University), Peter A. McSweeney(Mesoblast (United States)), George H. Kraft(Patara Pharma (United States)), Hailing Lu(University of Washington)
Cited by 66
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
A clinical approach to diagnosis of autoimmune encephalitis
|The Lancet Neurology|2016|4.4k
Chronic graft-versus-host syndrome in man
|The American Journal of Medicine|1980|2.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k